Scilex Holding Co
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating biopharmaceutical company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company operates through its wholly owned subsidiary Scilex, Inc. (formerly known… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Scilex Holding Co does
In the company’s own words
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating biopharmaceutical company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company operates through its wholly owned subsidiary Scilex, Inc. (formerly known as Scilex Holding Company), which was formed through a business combination with Vickers Vantage Corp. I that closed in November 2022. More information about the company is available at www.scilexholding.com.
The company's commercial product portfolio includes ZTlido (lidocaine topical system) 1.8%, a prescription topical product approved by the FDA for relief of neuropathic pain associated with postherpetic neuralgia, which launched in October 2018. ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults, launched in April 2023. GLOPERBA, the first and only liquid oral version of colchicine for gout prophylaxis, launched in June 2024. The company also maintains a pipeline of product candidates including SEMDEXATM (SP-102), a viscous gel formulation for epidural injection to treat sciatica that has completed Phase 3 trials; SP-103, a triple-strength lidocaine topical system for acute pain that completed Phase 2 trials; and SP-104, a low-dose naltrexone delayed-release formulation for fibromyalgia that completed Phase 1 trials.
Scilex employs a dedicated sales force of over 30 people targeting approximately 3,500 healthcare providers including primary care physicians, pain specialists, neurologists and palliative care physicians. The company leverages its commercial infrastructure across multiple therapeutic areas and maintains relationships with major pharmacy benefit managers and health plans to achieve formulary placement for its products.
In addition to its core pain management business, Scilex has adopted a cryptocurrency treasury strategy intending to invest in bitcoin, Ethereum and other blockchain-linked cryptocurrencies as long-term treasury assets. The company also established a subsidiary, Scilex Bio, Inc., which in April 2025 signed an exclusive worldwide license agreement for the KDS2010 drug candidate to develop and commercialize in metabolic diseases and neurodegenerative diseases.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1820190
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Scilex Holding Co — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Scilex Holding Co’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Scilex Holding Co and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Scilex Holding Co's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Scilex Holding Co's last four quarterly filings that the numbers alone won't show?”